Background/Aims: Systemic inflammatory response (SIR) is widely considered as a preoperative risk factor for hepatocellular carcinoma (HCC) outcomes. The neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), two of the prognostic indices, have been investigated in post-therapeutic recurrence and survival of HCC. Here, we quantify the prognostic value of these two biomarkers and evaluate their consistency in different HCC therapies. Methods: A systematic review of electronic database of the Web of Science, Embase, PubMed and the Cochrane Library was conducted to search for associations between the NLR and PLR in the blood and clinical outcomes of HCC. Overall survival (OS) and recurrencefree survival (RFS) were the primary outcomes, and hazard ratios (HRs) and 95% confidence intervals (95% CIs) were explored as effect measures. Subgroup analyses were performed to explore the heterogeneity of different therapies. Results: A total of 24 articles comprising 6318 patients were included in the meta-analysis. Overall, the pooled outcomes revealed that a high NLR before treatment predicted a poor OS (HR: 1.54, 95% CI: 1.34 to 1.76, p<0.001) and poor RFS (HR: 1.45, 95% CI: 1.16 to 1.82, p=0.001). Moreover, an increased PLR predicted a poor OS (HR: 1.63, 95% CI: 1.34 to 1.98, p<0.001) and earlier HCC recurrence (HR: 1.52, 95% CI: 1.21 to 1.91, p<0.001). In addition, both the NLR and PLR were identified as independent risk factors for predicting OS and RFS in HCC patients in a subgroup analysis of different
treatment types, including curative or palliative therapy; however, these results were not found in the sorafenib subgroup due to limited clinical research. Conclusion: An increased NLR or PLR indicated poor outcomes for patients with HCC. The NLR and PLR may be considered as reliable and inexpensive biomarkers for making clinical decisions regarding HCC treatment.
Introduction:
Hepatocellular carcinoma (HCC) is the fifth most frequently diagnosed malignant tumour and the third common cause of cancer-related deaths worldwide [1] . Recent studies show that the morbidity and mortality rates of HCC are increasing due to liver function deterioration, high recurrence rates and distant metastasis, even though the clinical diagnosis and treatment of HCC have been significantly improved [2] . Current therapeutic strategies depend on the HCC stage and several criteria at diagnosis, such as the tumour node metastasis (TNM), Barcelona Clinic Liver Cancer (BCLC), functional liver reserve and Child-Pugh scores. The primary treatment methods include curative hepatic resection, radiofrequency ablation and liver transplantation (LT) [3, 4] . When curative treatments are not feasible, alternate treatments include transarterial embolization (TAE)/transarterial chemoembolization (TACE) and multiple tyrosine kinase inhibitors, such as sorafenib, when HCC is diagnosed at advanced stages [5] .
However, the prognosis of HCC after treatment is still poor no matter whether the patients receive curative or palliative therapy. On the one hand, the criteria used for predicting HCC prognoses are complicated so they are restricted in routine clinical practice. On the other hand, multiple factors influence the malignancy and progression of HCC; these factors include tumour number, tumour size, and macro-vascular invasion, which are evaluated by radiological imaging before treatment. Thus, we must identify other predictors, particularly serum indices, for predicting HCC recurrence and survival.
Recently, tumour biological and immunological factors have been validated as preoperative risk factors for HCC recurrence [6, 7] . The proinflammatory effects of systemic inflammatory response (SIR) have been linked with various cancers, such as breast cancer [8] , pancreatic cancer [9] , colorectal cancer [10] and gastric cancer [11] . This cancergenerated inflammatory response results in the upregulation of cytokines and inflammatory mediators, causing an increased propensity for malignancy through inhibiting apoptosis, promoting angiogenesis, and damaging DNA [12] [13] [14] . Proposed inflammatory scores, such as the C-reactive protein (CRP) levels, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), inflammation-based index (IBI) and Glasgow prognostic score (GPS), have been considered as useful indicators for predicting the prognosis and survival in various cancers. Among these indices, the NLR and PLR have been widely investigated as prognostic values for determining HCC post-therapeutic recurrence and survival. However, due to variance in study designs and sample sizes, these studies have reported inconsistent results. It is therefore unknown whether the NLR and PLR are suitable prognostic indicators of HCC relapse in populations receiving curative or palliative therapy. In this study, we searched for available studies and performed a meta-analysis to reveal the prognostic role of the NLR and PLR in HCC recurrence and survival.
Materials and Methods

Search Strategy and Criteria
A meta-analysis was performed to compare two prognostic indices, the NLR and PLR, for predicting hepatocellular carcinoma prognosis after treatment. Five electronic databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched through January 2017 for studies regarding the NLR and PLR. The following MeSH terms and text words were confined to the Title/Abstract: "lymphocyte", "platelet", "lymphocyte-to-platelet", "liver cancer" and "hepatocellular carcinoma".
Data Management
Data from the included studies were summarized independently by two of the authors. They were blinded to the journals, authors and institutions of all available articles. Any disagreements between the reviewers were settled by the senior author. Overall survival and recurrence-free survival rates were analysed in this meta-analysis.
Quality Assessment and Statistical Analysis
The level of evidence of these articles was estimated by using the UK Cochrane Centre of Evidence (2009). The modified Newcastle-Ottawa scale was used to assess the quality of the retrospective studies; this scale consists of three factors: the selection of patients, comparability of the study groups, and assessment of outcome. The maximum total score on this scale is 9; studies with scores ≥7 were defined as high-quality studies.
All data were pooled using the Cochrane Collaboration's Review Manager 5.3 (Cochrane Collaboration, Oxford, UK). Mean differences and 95% confidence intervals (CIs) were calculated to pool the functional outcomes. Statistical heterogeneity among the studies was assessed using chi-square tests with the significance set at p< 0.1, and heterogeneity was quantified using the I 2 statistic. A fixed-effects model was used unless there was obvious heterogeneity among the included studies. Then, a random-effects was used for the candidates.
Subgroups and Publication Bias
There were several types of therapies used for treating HCC. In the included studies, curative resection, TACE, radiofrequency ablation (RFA), LT and chemotherapy were used. Thus, subgroup analyses were performed to minimize the influence of the different therapies. Funnel plots were used to signify publication bias. If the outcomes were associated with significant heterogeneity, a random-effects model was used to minimize bias. (Fig. 1) . Overall, 308 were duplicate articles; 165 did not focus on the value of the PLR in predicting prognostic outcomes in patients with hepatocellular carcinoma; 152 were laboratory studies; 35 were case reports; 6 were letters; and 1 was a comment. Then, the full texts of the remaining 47 articles were carefully reviewed. After this review, 23 more articles were excluded. Finally, 24 articles were included in this systematic review and metaanalysis . The main features of the selected studies are shown in Table 1 . In total, 6318 patients were included in this study. All of the included studies were retrospectively designed. The level of evidence was 2a.
Results
Characteristics of the Selected Articles
The main results are shown in Table 2 . Of the 24 articles, 19 studies analysed the NLR for predicting the prognosis of hepatocellular carcinoma after treatment. The patients with a low NLR had a better prognosis (HR: 1.54, 95% CI: 1.34 to 1.76, p<0.001) (Fig. 2) . A high NLR was considered to be risk factor that predicted earlier hepatocellular carcinoma recurrence (HR: 1.45, 95% CI: 1.16 to 1.82, p=0.001) (Fig. 3) . Patients with a lower pretreatment NLR had better recurrence-free survival rates. The PLR was also analysed independently. A high PLR was considered to be an independent risk factor for patients with HCC. Compared to a low PLR, a high PLR resulted in a lower overall survival (HR: 1.63, 95% CI: 1.34 to 1.98, p<0.001) (Fig. 4) . Patients with a low pretreatment PLR had higher recurrence-free survival rates (HR: 1.52, 95% CI: 1.21 to 1.91, p<0.001) (Fig. 5) . 
Subgroup Analysis
Subgroup analyses were conducted to minimize the influence of different HCC therapies. The therapies included curative resection, liver transplantation, TACE, RFA and chemotherapy. Our results indicated that the NLR was a significant risk factor for predicting the overall survival after treatment (Fig. 6) . The HR in the resection subgroup was 1.78, 95% CI: 1.35 to 2.33, p<0.001. In the liver transplantation group, the HR was 3.12, 95% CI: 1.62 to 6.00, p<0.001. The HR values were 1.31 and 1.15 for TACE and chemotherapy, respectively. All the results were statistically significant. The PLR could estimate the recurrence-free survival for HCC in subgroup analyses (Fig. 7) for the resection (HR: 1.40, 95% CI: 1.21 to to 2.26, p<0.001) groups. In the chemotherapy group, there was no significant difference in the PLR for the recurrence-free survival analysis (HR: 0.98, 95% CI: 0.94 to 1.02, p=0.32).
The PLR was also considered as an independent risk factor for predicting overall survival rates in subgroup analyses (Fig. 8) . P values for the subgroups were <0.001 in the resection, LT and TACE groups. There was no significant difference in the chemotherapy group for the PLR analysis.
Sensitivity Analysis and Publication Bias
The 24 retrospective studies that scored a seven or higher on the modified NewcastleOttawa scale were included in the sensitivity analysis. No significant changes were found in any of the outcomes (Table 3 ). The degree of between-study heterogeneity decreased for the overall survival and remained statistically significant (Table 4) .
The funnel plot of the PLR in the overall survival analysis showed that 19 articles included in this meta-analysis did not fall within the 95% CIs (Fig. 9) . was associated with a higher rate of lymph node metastasis [10, 42] . Xue TC et al. observed that a high PLR predicts poor survival in patients with advanced hepatocellular carcinoma who received TACE [23] . To the best of our knowledge, this is the first meta-analysis to integrate recent studies of the relationship between these two inflammatory markers (the NLR and PLR) and the survival of HCC patients receiving diverse treatments. The molecular mechanisms through which the NLR and PLR are associated with poor HCC outcomes remain unknown, but several hypotheses can be proposed. First, several basic studies have demonstrated that neutrophilia, which is responsible for inflammation, inhibits the cytolytic activity of immune cells, such as lymphocytes, activated T cells, and natural killer cells. Kuang DM et al. found that neutrophils were enriched predominantly in the peritumoural stroma of HCC tissues, which was positively associated with angiogenesis progression. In addition, the neutrophil levels could be considered as a powerful predictor of poor survival in HCC patients [43] . Moreover, neutrophils in HCC intratumoural regions had increased autophagic activity, which sustained poor survival and the pro-tumourigenic effects of HCC [44] .
Second, Lee et al. showed that HCC patients with a high platelet count had a high risk of extrahepatic metastasis [55] . The relatively high percentage of platelets secrete high levels of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which are major factors in angiogenesis, cell proliferation and tumour metastasis [46, 47] . Recent- [50] . Thus, an increased platelet levels are considered to promote proliferation in normal liver tissues as well as HCC.
In addition, the percentage of the lymphocyte population is relatively lower in patients with a high NLR or PLR; lymphocytes are involved in cell-mediated anti-tumour immune responses [51] [52] [53] . Numerous studies have reported that increased lymphocyte infiltration in tumours has been related to a better prognosis in patients [54] . For example, colorectal cancer patients with a higher number of tumour-infiltrating lymphocytes (TILs) exhibit improved survival [55] . Moreover, low levels of lymphocytic infiltration are a predictor of poor prognosis for colorectal liver metastases and HCC [13, 56] .
Last but not least, increased circulating concentrations of several cytokines and growth factors secreted by HCC and associated host cells contribute to the formation of the tumour microenvironment [12] ; these factors include IL-6, IL-17 [57] , IFN-γ, and HGF [13] . Thus, neutrophils, platelets and lymphocytes might all play important roles in tumour progression. A high NLR or PLR may reflect an imbalance in the immune response to tumours.
There are several limitations to this study. Only summarized data and not individual patient data were available to analyse. In some studies, HRs and 95% CIs were not provided directly. Furthermore, all the included studies were retrospective. In addition, most studies used Chinese populations, which might restrict its routine clinical application in Western countries. Finally, neutrophil, platelet and lymphocyte levels are easily influenced by infections, inflammation in other tissues and medications taken before HCC treatment; these factors might interfere with the NLR and PLR measurements.
Conclusion
Our meta-analysis revealed that the NLR and PLR are independent indexes for predicting HCC recurrence and survival whether the patient receives curative or palliative therapy. As a routine test, the NLR and PLR are practical and easy to obtain; as such, these measurements should be considered as biomarkers in the clinical management of HCC.
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